Download PDF
Thromb Haemost 1961; 05(02): 267-284
DOI: 10.1055/s-0038-1654924
Originalarbeiten – Original Article – Travaux Originaux
Schattauer GmbH

Antithrombin V: Critical Evaluation of its Assessment and Properties[*]

Carl Vermylen
1   Laboratory of Physiopathology, Department of Medicine (Prof. J. Vandenbroucke) University of Louvain, Belgium
,
Marc Verstraete   *
1   Laboratory of Physiopathology, Department of Medicine (Prof. J. Vandenbroucke) University of Louvain, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

1. The techniques used for assessment and detection of antithrombin V are discussed in detail.

2. The differentiation of antithrombin V from other causes, which may prolong the thrombin time, are presented.

3. The criteria were determined, which at the present time are required for the recognition of antithrombin V. Complementary experiments to perform in one case with antithrombin V are suggested.

4. The differentiation of the antithrombin from an antifibrinogen, as was proposed by Loeliger and Hers, is critically reviewed. A new base to classify the inhibitors of the fibrinogen conversion mechanism is proposed.

* This work was supported by grant from the Fonds de la Recherche Clinique Médicale.


** Associate of the National Fund of Scientific Research, Belgium.


 

  • References

  • 1 Loeliger A, Hers PhGF. Chronic antithrombinaemia (antithrombin V) with haemorragic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia. Thromb. Diath. haem. 01: 499 1957;
    PubMedSearch in Google Scholar
  • 2 Larrieu M. J, Beaumont J. L, Caen J, Seligman M, Bernard J. Inhibition de la conversion du fibrinogène au cours d’un myélome. Rev. franç. Et. clin, biol. 03: 617 1958;
    PubMedSearch in Google Scholar
  • 3 Benda L, Deutsch F, Mammen F. Über eine Gerinnungsstörung bei einem Patienten mit multiplem Myelom. Wien. klin. Wschr. 50: 559 1958;
    PubMedSearch in Google Scholar
  • 4 Verstraete M, Vermylen C. Recherches sur l’antithrombine V dans la maladie de Kahler. Acta haemat. (Basel) 22: 240 1959;
    CrossrefPubMedSearch in Google Scholar
  • 5 Verstraete M, Vermylen C. Recherches sur l’antithrombine V dans la maladie de Kahler. Sang. 30: 410 1959;
    PubMedSearch in Google Scholar
  • 6 Verstraete M, Vermylen C. The occurence of antithrombin V. With special reference to its high frequency in y-myeloma. To be published..
    PubMed
  • 7 Vries de S. I. (Amsterdam). Personal communication..
    PubMed
  • 8 Masure R. Les inhibiteurs normaux et pathologiques de la coagulation. Thèse d’agrégation. To be published..
    PubMed
  • 9 Peeters H. Binding of calcium in blood in the presence of anticoagulants. Amer. J. clin. Path. 31: 394 1959;
    PubMedSearch in Google Scholar
  • 10 Verstraete M, Vermylen C. Antihrombin I activity. Thromb. Diath. haem. 03: 640 1959;
    PubMedSearch in Google Scholar
  • 11 Dreskin O. H. Prothrombin measurement with hemolyzed whole blood thromboplastin. J. Lab. clin. med. 51: 312 1958;
    PubMedSearch in Google Scholar
  • 12 Jurgens J. Neue Bestimmungsmethoden und Bedeutung der Antithrombinen für die Klinik. Klin. Wschr. 35: 303 1957;
    CrossrefPubMedSearch in Google Scholar
  • 13 Schmid J. Methode zur Bestimmung der Thrombininhibitoraktivität. Wien. Z. inn. Med. 32: 108 1951;
    PubMedSearch in Google Scholar
  • 14 Witte S, Dirnberger P. Antithrombin und Thrombininhibitoraktivität. Klin. Wschr. 31: 598 1953;
    CrossrefPubMedSearch in Google Scholar
  • 15 Holemans R. Proefondervindelijke Studie van de invloed der enkele anticoagulantia van het heparino’fde type op de bloedstolling. Thesis Wedstrijd Reisbeurzen Belgische Staat. 1957
    PubMedSearch in Google Scholar
  • 16 Douglas A. S. The action of heparin in the prevention of prothrombin conversion. J. clin. Invest 35: 533 1956;
    CrossrefPubMedSearch in Google Scholar
  • 17 Andersen M. N, Mindelow M, Alfano G. A. A comparative study of heparin neutralization and the danger of blood clotting abnormalities with protamine and polybrene. J. thorac. Surg. 39: 613 1960;
    PubMedSearch in Google Scholar
  • 18 Burstein M. Substances fibrinoplastiques et antifibrinoplastiques. Rev. Hémat. 07: 587 1952;
    PubMedSearch in Google Scholar
  • 19 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta haemat. (Basel) 17: 237 1957;
    CrossrefPubMedSearch in Google Scholar
  • 20 Jorpes F, Vrethammer T, Ohman B, Blomback B. On the assay of thrombin preparations. J. Pharmacol (Kyoto) 10: 561 1958;
    CrossrefPubMedSearch in Google Scholar
  • 21 Soulier J. P. Les inhibiteurs naturels de la coagulation. Sang. 30: 262 1959;
    PubMedSearch in Google Scholar
  • 22 Soulier J. P. A new adsorption agent for coagulation disorders. J. clin. Path. 12: 303 1959;
    CrossrefPubMedSearch in Google Scholar
  • 23 Tsamboulas N, Lazanas G, Premetis F. Der Einfluß des Thrombins auf die Fibrinbildung. Die Wirkung der Thrombozyten, des Thrombins und des Kalziums auf das 2. und 3. Stadium der Blutgerinnung. Dtsch. Arch. slin. Med. 204: 89 1957;
    PubMedSearch in Google Scholar
  • 24 Verwilghen R, Verstraete M, Vandenbroucke J. Anticorps spécifiques contre la thrombine d’origine équine. Rev. Hémat. 08: 273 1953;
    PubMedSearch in Google Scholar
  • 25 Soulier J. P. Apparition d’une antithrombine, à la suite d’injections de thrombine, chez un hémophile ayant présenté un anticoagulant circulant. Rev. Hémat. 08: 39 1953;
    PubMedSearch in Google Scholar
  • 26 Nilsson I. M, Skanse B, Gydell K. Circulating anticoagulant after pregnancy and its response to ACTH. Acta haemat. 19: 40 1958;
    CrossrefPubMedSearch in Google Scholar
  • 27 Benthous J, Richter W. C. Zum Krankheitsbild der Hemmkörperhämophilie. Ein kasuistischer Beitrag. Dtsch. Arch. klin. Med. 203: 1 1956;
    PubMedSearch in Google Scholar
  • 28 Kautsch F. Störungen der Blutgerinnung beim Plasmozytom. Klin. Wschr. 35: 77 1957;
    CrossrefPubMedSearch in Google Scholar
  • 29 Craddock G. C, Adams W. S, Figueroa W. G. Interference with fibrin formation in multiple myeloma by an un usual protein found in blood and urine. J. Lab. clin. Med. 42: 844 1953;
    PubMedSearch in Google Scholar
  • 30 Frick P. G. Inhibition of conversion of fibrinogen to fibrin by abnormal proteins in multiple myeloma. Amer. J. clin. Path. 25: 1263 1955;
    PubMedSearch in Google Scholar
  • 31 Uehlinger F. Über eine Blutgerinnungsstörung bei Dysproteinämie. (Beitrag der körpereigenen Antikoagulantien.) Dissertation, Bern. 1949
    PubMedSearch in Google Scholar
  • 32 Höhnen H. W. Experimentelle Studien zur Frage der Beeinflussung der Blutgerinnung durch Reptilase. 2. ges. exp. Med. 128: 424 1957;
    PubMedSearch in Google Scholar
  • 33 Blombäck B, Blombäck M, Nilsson I. M. Coagulation studies on “Reptilase” an extract of the venom from Bothrops jararaca. Thromb. Diath. haem. 01: 46 1957;
    PubMedSearch in Google Scholar
  • 34 Sokal G. Thromblastographische Untersuchungen über den Einfluß verschiedener Serumproteine und dialysierbarer Substanzen auf die Struktur des Blutgerinnsels. Klin. Wschr. 37: 718 1959;
    PubMedSearch in Google Scholar
  • 35 Schultze H. F, Schwick G, Sonnet J, Heremans J, Michaux J. L. Gamma-X-globulin, eine immunelectrophoretische nachweisbare y-Globulin-Komponente mit Beziehungen zum C-reaktiven Protein. Klin. Wschr. 38: 62 1960;
    CrossrefPubMedSearch in Google Scholar
  • 36 Sonnet J, Michaux J. L. C-réactive protéine et globuline γ x chez les Bantous du Bas-Congo. Clin. chim. Acta. 05: 223 1960;
    CrossrefPubMedSearch in Google Scholar
  • 37 Heremans J. Les globulines sériques du système gamma. Leur nature et leur pathologie. Ed. Masson, Paris, Ed. Arscia: Bruxelles; 1960
    Search in Google Scholar
  • 38 Blombäck B. Studies an fibrinogen: its purification and conversion into fibrin. Acta physiol, scand. 43 suppl. 148 1958;
    PubMedSearch in Google Scholar